Cardio Diagnostics (CDIO) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Insight Molecular Diagnostics is the larger company by market cap ($80.9 million vs $4.7 million), about 17.1 times the size. Insight Molecular Diagnostics converts more of its revenue into profit, with a net margin of -1238.5% versus -43832.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDIO | IMDX |
|---|---|---|
| Share price | $1.60 | $1.97 |
| Market cap | $4.74M | $80.88M |
| 1-day change | -3.03% | +18.67% |
| YTD return | — | -73.73% |
| 1-year return | — | -67.38% |
| 5-year return | — | -95.91% |
| EPS (TTM) | $-2.52 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.82K | $4.05M |
| Revenue growth (YoY) | -57.51% | +115.58% |
| Net income (latest FY) | $-6.50M | $-50.22M |
| Gross margin | — | 56.67% |
| Operating margin | -43737.46% | -1260.76% |
| Net margin | -43832.49% | -1238.52% |
| 52-week high | $7.91 | $7.51 |
| 52-week low | $0.97 | $1.50 |
| Distance from 52-week high | -79.77% | -73.77% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +318.78% |
| Average volume | 26.91K | 261.88K |
| Shares outstanding | 2.96M | 41.05M |
| Employees | 15 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insight Molecular Diagnostics is about 17.1 times larger than Cardio Diagnostics by market value ($80.88M vs $4.74M).
- Insight Molecular Diagnostics is more profitable, keeping -1238.5 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
- Insight Molecular Diagnostics grew revenue faster in its latest fiscal year (+115.58% vs -57.51%).
About Cardio Diagnostics
CDIO stock →Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
CDIO vs IMDX FAQ
Which is bigger, Cardio Diagnostics or Insight Molecular Diagnostics?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $80.88M compared with $4.74M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.